Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 13, 2023
Deals

June 12 Quick Takes: AZ’s first-in-class AKT inhibitor under review

Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more
BioCentury | Jun 1, 2023
Data Byte

At least 15 PDUFA dates on FDA’s calendar for June

Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
BioCentury | May 23, 2023
Deals

Sizing up VectivBio’s takeout premium among '23 M&A deals

Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | Apr 21, 2023
Product Development

ADC advances at AACR: target diversity, optimizing internalization

BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Dec 3, 2022
Finance

Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal

Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Sep 9, 2022
Product Development

China driving solid tumor CAR T innovation

Chinese investigator-initiated trials are accelerating CAR T innovation, bringing solid tumor advances to ESMO22
BioCentury | Feb 18, 2022
Product Development

Feb. 17 Quick Takes: Agios wins FDA approval in rare anemia

Plus updates from Arvinas, BMS, Innovent, Ironwood, Deerfield, Yumanity
BioCentury | Jan 18, 2019
Clinical News

China approves Linzess for IBS-C

BioCentury | Dec 21, 2018
Company News

Bausch named 'stalking horse' in Synergy auction

Items per page:
1 - 10 of 205